Information about Imprifab
My details
*
*
*

Imprifab (SRL)

Company information

Status
Active

Enterprise number

BE0812.337.386

VAT liability
Yes
Established
12-06-2009
Last balance sheet year
2025
Company size
Micro 0 FTE
Legal form
Société à responsabilité limitée (SRL)
Commercial name
IMPRIFAB.COM
Principal activity
Manufacture of other chemical products n.e.c.
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Imprifab

2025 2024 2023 2022
Income statement
Profit/Loss € 1,802 164% € -2,813 -40% € -2,011 -209% € -651
Gross margin € 2,476 217% € -2,112 -54% € -1,370 < -1000% € -57
Balance sheet
Balance sheet total € 12,480 -22% € 15,962 323% € 3,775 -9% € 4,166
Equity € -9,130 16% € -10,932 -35% € -8,119 -33% € -6,108
Debts € 21,610 -20% € 26,894 126% € 11,894 16% € 10,274

Publications from Imprifab

Date Publication
05-01-2024 Modification(s) Articles of Association (NL)
25-06-2009 Rubric Constitution (New Juridical Person, Opening Branch, etc...) (NL)

Frequently asked questions

What is the VAT number of Imprifab?
The VAT number of Imprifab is BE 0812.337.386.
Wat is the PEPPOL ID of Imprifab?
The PEPPOL ID of Imprifab is 0208:0812337386. Log in or start a free trial to see the full overview.
When was Imprifab founded?
Imprifab was founded on 12-06-2009.
What is the address of Imprifab?
The current registered office of Imprifab is located at Kwadeweg 106, 9940 Evergem.
When was the last time Imprifab filed their annual financial statements?
The most recent financial statements of Imprifab were filed on 18-08-2026.
How many employees does Imprifab have?
There are currently no employees working at Imprifab or no workforce information is available.
What is the annual turnover of Imprifab?
At the time of its most recent financial statements, Imprifab did not publish any turnover figures. Imprifab reported a gross margin of €2,476.00.